Additional cycles of docetaxel in combination with androgen deprivation therapy (D-ADT) in metastatic hormone- sensitive prostate cancer (mHSPC): Efficacy and feasibility analysis.

被引：0
|
作者：
Aydogdu, Can
Urban, Florian
Tamalunas, Alexander
Berg, Elena
Goetz, Melanie
Rodler, Severin
Unterrainer, Lena
Heinemann, Volker
Stief, Christian G.
Casuscelli, Jozefina
机构：
[1] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Urol, Munich, Germany
[2] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Nucl Med, Munich, Germany
[3] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Med 3, Munich, Germany
[4] Ludwig Maximillian Univ Munich, Univ Hosp, Dept Urol, Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17074
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Additional cycles of docetaxel in combination with androgen deprivation therapy (D-ADT) in metastatic hormone- sensitive prostate cancer (mHSPC): Efficacy and feasibility analysis.
    Aydogdu, Can
    Urban, Florian
    Tamalunas, Alexander
    Berg, Elena
    Tz, Melanie Go Spacing Diaeresis
    Rodler, Severin
    Heinemann, Volker
    Stief, Christian
    Casuscelli, Jozefina
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [2] EFFICACY AND FEASIBILITY OF ADDITIONAL CYCLES OF DOCETAXEL IN COMBINATION WITH ANDROGEN DEPRIVATION THERAPY IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
    Aydogdu, Can
    Urban, Florian
    Tamalunas, Alexander
    Berg, Elena
    Goetz, Melanie
    Rodler, Severin
    Heinemann, Volker
    Stief, Christian G.
    Casuscelli, Jozefina
    JOURNAL OF UROLOGY, 2023, 209 : E388 - E389
  • [3] Treatment patterns for metastatic hormone-sensitive prostate cancer (mHSPC) progressing after up-front docetaxel in combination with androgen deprivation therapy (D-ADT).
    Barata, Pedro C.
    Emamekhoo, Hamid
    Mendiratta, Prateek
    Gopalakrishnan, Dharmesh
    Koshkin, Vadim S.
    Tyler, Allison Janine
    Ornstein, Moshe Chaim
    Grivas, Petros
    Gilligan, Timothy D.
    Rini, Brian I.
    Kyriakopoulos, Christos
    Garcia, Jorge A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [4] ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC).
    Armstrong, Andrew J.
    Szmulewitz, Russell Zelig
    Petrylak, Daniel Peter
    Holzbeierlein, Jeffrey M.
    Villers, Arnauld
    Azad, Arun
    Alcaraz, Antonio
    Alekseev, Boris Yakovlevich
    Iguchi, Taro
    Shore, Neal D.
    Rosbrook, Brad
    Baron, Benoit
    Chen, Lucy F.
    Stenzl, Arnulf
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Comparative efficacy and cost-effectiveness of maximum androgen blockade (MAB), docetaxel with androgen deprivation therapy (ADT), and ADT alone for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in China
    Jiang, W.
    Qu, S.
    Liu, Y.
    Yao, X.
    Liu, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 276 - 276
  • [6] Qualitative and Quantitative Assessment of Patient and Carer Experience of Chemotherapy (Docetaxel) in Combination with Androgen Deprivation Therapy (ADT) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    Ito, Tetsuro
    Grant, Laura
    Duckham, Bryony R.
    Ribbands, Amanda J.
    Gater, Adam
    ADVANCES IN THERAPY, 2018, 35 (12) : 2186 - 2200
  • [7] Qualitative and Quantitative Assessment of Patient and Carer Experience of Chemotherapy (Docetaxel) in Combination with Androgen Deprivation Therapy (ADT) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    Tetsuro Ito
    Laura Grant
    Bryony R. Duckham
    Amanda J. Ribbands
    Adam Gater
    Advances in Therapy, 2018, 35 : 2186 - 2200
  • [8] Efficacy and safety of darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) by metastatic burden: Subgroup analyses of ARASENS
    Tombal, B.
    Saad, F.
    Fizazi, K.
    Sternberg, C. N.
    Crawford, E. D.
    Gratzke, C.
    Grabbert, M.
    Vilaseca, A.
    Shore, N.
    Kopyltsov, E.
    Boegemann, M.
    Kapur, S.
    Srinivasan, S.
    Verholen, F.
    Kuss, I.
    Joensuu, H.
    Smith, M. R.
    Hussain, M.
    EUROPEAN UROLOGY, 2023, 83
  • [9] Tolerability and pharmacokinetic analyses of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone sensitive prostate cancer (mHSPC) from ARASENS
    Tombal, B.
    Smith, M. R.
    Hussain, M.
    Saad, F.
    Fizazi, K.
    Sternberg, C. N.
    Crawford, E. D.
    Kapur, S.
    Zhang, W.
    Ploeger, B.
    Li, R.
    Kuss, I.
    Zieschang, C.
    Wittemer-Rump, S.
    Rezazadeh, Kalebasty A.
    EUROPEAN UROLOGY, 2023, 83
  • [10] DAROLUTAMIDE CAN BE EFFECTIVELY AND SAFELY ADMINISTERED IN COMBINATION WITH ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL IN PATIENTS WITH METASTATIC HORMONE- SENSITIVE PROSTATE CANCER
    Martone, Brenda
    Smith, Matthew
    Tombal, Bertrand
    Hussain, Maha
    Kapur, Shivani
    Kalebasty, Arash Rezazadeh
    ONCOLOGY NURSING FORUM, 2023, 50 (02)
12345